What is it? MK-8189 is a Ph. II clinical candidate for schizophrenia targeting PDE10A, a long-pursued but uncracked target for psychosis. With potentially better target engagement over prior molecules, it could become the first in the class to demonstrate efficacy in this challenging therapeutic area. The discovery and medicinal chemistry [...]
8 minute read
Feb. 25, 2023
MK-8189: a PDE10A Inhibitor to Treat Schizophrenia
MK-8189
oral PDE10A inhibitor Ph. IIb for schizophrenia from fragment screen + SBDD J. Med. Chem., January 10, 2023 Merck, West Point, PA
Loading...
